Loading
A phase 1/2 trial of INV-6452 in ovarian cancer, endometrial cancer and HR-positive / HER2-negative breast cancer, run by Shenzhen Ionova Life Sciences Co., Ltd., now recruiting.
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of INV-6452 in Adult Patients With Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Advanced/Metastatic Breast Cancer or Locally Advanced/Metastatic Solid Tumor is a phase 1/2 interventional study registered as NCT07612891 by Shenzhen Ionova Life Sciences Co., Ltd., with 201 participants planned, started 2025-07-04 and due to reach its primary completion in 2028-02-04. Interventions recorded: INV-6452.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Shenzhen Ionova Life Sciences, Endometrial cancer, Ovarian cancer and the tag pipeline.
Shares Shenzhen Ionova Life Sciences and the tag pipeline.
Shares Endometrial cancer, Ovarian cancer and the tag pipeline.
Shares Endometrial cancer, Ovarian cancer and the tag pipeline.
Shares Endometrial cancer, Ovarian cancer and the tag pipeline.
Shares Ovarian cancer and the tag pipeline.
Shares Ovarian cancer and the tag pipeline.
Shares Ovarian cancer, HR-positive / HER2-negative breast cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/